{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:15:48Z","timestamp":1780712148672,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.spen.2023.101051","type":"journal-article","created":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T09:32:56Z","timestamp":1682847176000},"page":"101051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Pediatric Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1016","volume":"46","author":[{"given":"Kelsey","family":"Poisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen S.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.spen.2023.101051_bib0001","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis Optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9451","key":"10.1016\/j.spen.2023.101051_bib0002","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis Optica: Distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.spen.2023.101051_bib0003","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis Optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.spen.2023.101051_bib0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.spen.2023.101051_bib0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis Optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.spen.2023.101051_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide Incidence and prevalence of neuromyelitis Optica: A systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.spen.2023.101051_bib0007","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","article-title":"Antibodies to MOG and AQP4 in children with neuromyelitis Optica and limited forms of the disease","volume":"87","author":"Lechner","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.spen.2023.101051_bib0008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.spen.2023.101051_bib0009","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis Optica: A review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler"},{"issue":"22","key":"10.1016\/j.spen.2023.101051_bib0010","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis Optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.spen.2023.101051_bib0011","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.0b013e31822facdd","article-title":"Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children","volume":"77","author":"Langer-Gould","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2023.101051_bib0012","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.msard.2019.06.002","article-title":"Incidence of pediatric neuromyelitis Optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008\u20122018: A nationwide, population-based cohort study","volume":"33","author":"Boesen","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.spen.2023.101051_bib0013","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.spen.2023.101051_bib0014","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1212\/WNL.0000000000002283","article-title":"Clinical features of neuromyelitis Optica in children: US network of pediatric MS centers report","volume":"86","author":"Chitnis","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jnnp-2021-327206","article-title":"Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"93","author":"Camera","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.spen.2023.101051_bib0016","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.spen.2023.101051_bib0017","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis Optica spectrum disorder: An international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0883073811420495","article-title":"The demographic, clinical, and magnetic resonance imaging (MRI) features of transverse myelitis in children","volume":"27","author":"Thomas","year":"2012","journal-title":"J Child Neurol"},{"issue":"11","key":"10.1016\/j.spen.2023.101051_bib0019","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1177\/1352458521994259","article-title":"Bright spotty lesions as an imaging marker for neuromyelitis Optica spectrum disorder","volume":"28","author":"Salama","year":"2022","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.spen.2023.101051_bib0020","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13760-021-01792-1","article-title":"Frequency of diencephalic syndrome in NMOSD","volume":"122","author":"Etemadifar","year":"2022","journal-title":"Acta Neurol Belg"},{"issue":"5","key":"10.1016\/j.spen.2023.101051_bib0021","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458517726593","article-title":"Endocrinopathies in paediatric-onset neuromyelitis Optica spectrum disorder with aquaporin 4 (AQP4) antibody","volume":"24","author":"Hacohen","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2023.101051_bib0022","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fped.2020.00339","article-title":"(GJCF-ICC) G-JFICC. Pediatric NMOSD: A review and position statement on approach to work-up and diagnosis","volume":"8","author":"Tenembaum","year":"2020","journal-title":"Front Pediatr."},{"issue":"9","key":"10.1016\/j.spen.2023.101051_bib0023","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.spen.2023.101051_bib0024","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1177\/1352458516630823","article-title":"False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients","volume":"22","author":"Cohen","year":"2016","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.spen.2023.101051_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"Pt 5","key":"10.1016\/j.spen.2023.101051_bib0026","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"1-2","key":"10.1016\/j.spen.2023.101051_bib0027","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis Optica: Results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.spen.2023.101051_bib0028","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.msard.2019.07.008","article-title":"AQP4-IgG-seropositive neuromyelitis Optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review","volume":"35","author":"Tao","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.spen.2023.101051_bib0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2023.101051_bib0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.21197","article-title":"Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica","volume":"39","author":"McKeon","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.spen.2023.101051_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104215","article-title":"Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD","volume":"68","author":"Paolilo","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.spen.2023.101051_bib0033","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/dmcn.13757","article-title":"Retinal nerve fibre layer thinning is associated with worse visual outcome after optic neuritis in children with a relapsing demyelinating syndrome","volume":"60","author":"Eyre","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.spen.2023.101051_bib0034","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2018.03.003","article-title":"Clinical characteristics of pediatric optic neuritis with myelin oligodendrocyte glycoprotein seropositive: A cohort study","volume":"83","author":"Chen","year":"2018","journal-title":"Pediatr Neurol"},{"issue":"11","key":"10.1016\/j.spen.2023.101051_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113631","article-title":"Clinical correlations of motor and somatosensory evoked potentials in neuromyelitis optica","volume":"9","author":"Tsao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2023.101051_bib0036","article-title":"Efficacy of plasma exchange in acute attacks of neuromyelitis Optica spectrum disorders: A systematic review and meta-analysis","volume":"350","author":"Yu","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"12","key":"10.1016\/j.spen.2023.101051_bib0037","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis Optica spectrum disorders (NMOSD): a systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.spen.2023.101051_bib0038","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2023.101051_bib0039","article-title":"Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis Optica spectrum disorder","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.spen.2023.101051_bib0040","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1177\/0883073814545883","article-title":"Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination","volume":"30","author":"Bigi","year":"2015","journal-title":"J Child Neurol"},{"issue":"4","key":"10.1016\/j.spen.2023.101051_bib0041","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1212\/CPJ.0000000000000480","article-title":"Safety and efficacy of plasma exchange in pediatric transverse myelitis","volume":"8","author":"Noland","year":"2018","journal-title":"Neurol Clin Pract"},{"issue":"10","key":"10.1016\/j.spen.2023.101051_bib0042","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis Optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.spen.2023.101051_bib0043","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00415-015-7991-1","article-title":"Efficacy of glatiramer acetate in neuromyelitis Optica spectrum disorder: A multicenter retrospective study","volume":"263","author":"Ayzenberg","year":"2016","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0044","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis Optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2023.101051_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102975","article-title":"Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation","volume":"52","author":"Bonnan","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.spen.2023.101051_bib0046","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1212\/NXI.0000000000000363","article-title":"Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS","volume":"4","author":"Gahlen","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0047","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00415-015-7925-y","article-title":"Alemtuzumab use in neuromyelitis Optica spectrum disorders: A brief case series","volume":"263","author":"Azzopardi","year":"2016","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.spen.2023.101051_bib0048","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458517694086","article-title":"Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis Optica spectrum disorder","volume":"23","author":"Yamout","year":"2017","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0049","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1212\/NXI.0000000000000188","article-title":"Rituximab monitoring and redosing in pediatric neuromyelitis Optica spectrum disorder","volume":"3","author":"Nosadini","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2023.101051_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103830","article-title":"Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases","volume":"63","author":"Saidenberg","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.spen.2023.101051_bib0051","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1177\/1352458520932798","article-title":"Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations","volume":"27","author":"Ghezzi","year":"2021","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.spen.2023.101051_bib0052","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.spen.2023.101051_bib0053","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1212\/NXI.0000000000000724","article-title":"Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease?","volume":"7","author":"Dey\u00e0-Mart\u00ednez","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4-6","key":"10.1016\/j.spen.2023.101051_bib0054","first-page":"51","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis Optica spectrum disorder treated with rituximab, azathioprine, and mycophenolate mofetil: A systematic review and meta-analysis","volume":"19","author":"Magdalena","year":"2022","journal-title":"Innov Clin Neurosci"},{"issue":"4","key":"10.1016\/j.spen.2023.101051_bib0055","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/NXI.0000000000000046","article-title":"Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children","volume":"1","author":"Longoni","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.spen.2023.101051_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102843","article-title":"Efficacy of rituximab in the treatment of neuromyelitis Optica spectrum disorders: An update systematic review and meta -analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.spen.2023.101051_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102727","article-title":"Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis","volume":"20","author":"Mirmosayyeb","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.spen.2023.101051_bib0058","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis Optica spectrum disorders: A systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.spen.2023.101051_bib0059","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2023.101051_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis Optica spectrum disorder: A systematic review and meta-analysis","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.spen.2023.101051_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103181","article-title":"Efficacy of mycophenolate mofetil in the treatment of neuromyelitis Optica spectrum disorders: An update systematic review and meta -analysis","volume":"55","author":"Wang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0062","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis Optica and neuromyelitis Optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.spen.2023.101051_bib0063","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.msard.2018.12.038","article-title":"Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis Optica spectrum disorder","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.spen.2023.101051_bib0064","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis Optica: Significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.spen.2023.101051_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577925","article-title":"Vaknin-Dembinsky A. IL-6 as a marker for NMOSD disease activity","volume":"370","author":"Haramati","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.spen.2023.101051_bib0066","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.spen.2023.101051_bib0067","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.spen.2023.101051_bib0068","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-0039-1684004","article-title":"Two cases of pediatric aqp4-antibody positive neuromyelitis optica spectrum disorder successfully treated with tocilizumab","volume":"50","author":"Breu","year":"2019","journal-title":"Neuropediatrics"},{"issue":"22","key":"10.1016\/j.spen.2023.101051_bib0069","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.spen.2023.101051_bib0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10206","key":"10.1016\/j.spen.2023.101051_bib0071","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.spen.2023.101051_bib0072","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2023.101051_bib0073","doi-asserted-by":"crossref","unstructured":"SJ Pittock, M Barnett, JL Bennett, et al., Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder, Ann Neurol, Published online March 3, 2023, doi:10.1002\/ana.26626.","DOI":"10.1002\/ana.26626"},{"key":"10.1016\/j.spen.2023.101051_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103252","article-title":"Reduced quality of life in a pediatric-onset Neuromyelitis optica spectrum disorders cohort","volume":"56","author":"Paolilo","year":"2021","journal-title":"Mult Scler Relat Disord"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909123000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909123000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:38:59Z","timestamp":1761028739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909123000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":74,"alternative-id":["S1071909123000207"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2023.101051","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric Neuromyelitis Optica Spectrum Disorder","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2023.101051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101051"}}